An attempt at topical DNCB immunomodulation in advanced malignant melanoma.

Nineteen patients with malignant melanoma metastatic to the skin, subcutaneous tissue or lymph nodes were treated with DNCB applied to the lesion. None of the patients was amenable to any other form of treatment. During the 20-month follow-up, complete remission occurred in 3 patients and partial remission in 3 patients, 1 patient showed stabilization of the disease, and in the remaining 12 not even transient improvement was observed.